Was busy yesterday recovering from trip and posting on AFFY YMB (even more bizarre than bash trash here last fall :-) Anyway, just wanted to give a quick update on my views on QCOR:
QCOR--I'm sticking with my $1.29 EPS for this Q. It could even be higher based on however much residual they picked up from Q1 and whether or not May/June was sustained growth??? Conversely, we don't really know if ALL problems of Q1 were solved or what % solved was in Q2. I remain extremely optimistic for long term and believe we'll see it breach $100 in the next 6-9 months. But it will remain VOLATILE (WITHIN UPWARD TRAJECTORY) until at least Q3 results.
PS. I think the Syncathen acquisition was STRATEGICALLY BRILLIANT !!!
Glad to be back...will post a quick brief on AFFY here for those who are interested. Done posting on AFFY YMB until some hard news...TOO MANY WHACK JOBS THERE :-) But remain very bullish with PATIENCE!!!
I agree about Synacthen Depot. While they work on US approval, QCOR can use their experience to raise the price and ramp up Synacthen Depot sales outside the US.
In some countries, multiple indications are already approved, and in other countries, they need to expand the indication base--which I'm guessing won't take more than 12-18 months.
I am putting together a library of all Synacthen and Synacthen Depot package inserts, approved indications, and will publish upon completion. But, for example, Synacthen Depot is already approved in Australia for IS and MS exacerbations and in several countries for a variety of autoimmune disorders.
Sentiment: Strong Buy
Max or someone correct me if I'm wrong but I think I remember Bailey saying during the last CC that the RC was only 5% of last Qtrs dismal earnings. Sorry too lazy today to go back and investigate. Have a good Holiday all!
i remembered the "new code" (forgive my ignorance in this field) was the main issue. Could somebody give a better recap of the issue, and the latest update on the resolution of the issues? thanks very much.